Literature DB >> 14745443

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration.

Mathias Heikenwalder1, Magdalini Polymenidou, Tobias Junt, Christina Sigurdson, Hermann Wagner, Shizuo Akira, Rolf Zinkernagel, Adriano Aguzzi.   

Abstract

DNA containing unmethylated cytidyl guanosyl (CpG) sequences, which are underrepresented in mammalian genomes but prevalent in prokaryotes, is endocytosed by cells of the innate immune system, including macrophages, monocytes and dendritic cells, and activates a pathway involving Toll-like receptor-9 (TLR9). CpG-containing oligodeoxynucleotides (CpG-ODN) are potent stimulators of innate immunity, and are currently being tested as adjuvants of antimicrobial, antiallergic, anticancer and antiprion immunotherapy. Little is known, however, about the consequences of repeated CpG-ODN administration, which is advocated for some of these applications. Here we report that daily injection of 60 microg CpG-ODN dramatically alters the morphology and functionality of mouse lymphoid organs. By day 7, lymphoid follicles were poorly defined; follicular dendritic cells (FDC) and germinal center B lymphocytes were suppressed. Accordingly, CpG-ODN treatment for > or =7 d strongly reduced primary humoral immune responses and immunoglobulin class switching. By day 20, mice developed multifocal liver necrosis and hemorrhagic ascites. All untoward effects were strictly dependent on CpG and TLR9, as neither the CpG-ODN treatment of Tlr9(-/-) mice nor the repetitive challenge of wild-type mice with nonstimulatory ODN (AT-ODN) or with the TLR3 agonist polyinosinic:cytidylic acid (polyI:C) were immunotoxic or hepatotoxic.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14745443     DOI: 10.1038/nm987

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  126 in total

1.  Overactivation of plasmacytoid dendritic cells inhibits antiviral T-cell responses: a model for HIV immunopathogenesis.

Authors:  Adriano Boasso; Caroline M Royle; Spyridon Doumazos; Veronica N Aquino; Mara Biasin; Luca Piacentini; Barbara Tavano; Dietmar Fuchs; Francesco Mazzotta; Sergio Lo Caputo; Gene M Shearer; Mario Clerici; David R Graham
Journal:  Blood       Date:  2011-09-19       Impact factor: 22.113

2.  Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

Authors:  Mayuka Horikawa; Veronique Minard-Colin; Takashi Matsushita; Thomas F Tedder
Journal:  J Clin Invest       Date:  2011-10-24       Impact factor: 14.808

Review 3.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

Review 4.  Microglia in prion diseases.

Authors:  Adriano Aguzzi; Caihong Zhu
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

Review 5.  Immune activation and the role of TLRs and TLR agonists in the pathogenesis of HIV-1 infection in the humanized mouse model.

Authors:  J Judy Chang; Marcus Altfeld
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

Review 6.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

Review 7.  Medical biofilms.

Authors:  James D Bryers
Journal:  Biotechnol Bioeng       Date:  2008-05-01       Impact factor: 4.530

8.  Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation.

Authors:  Patrick Lacasse; Jérôme Denis; Réjean Lapointe; Denis Leclerc; Alain Lamarre
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

9.  Progress and problems in the biology, diagnostics, and therapeutics of prion diseases.

Authors:  Adriano Aguzzi; Mathias Heikenwalder; Gino Miele
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 10.  Emerging nanotechnologies for cancer immunotherapy.

Authors:  Sourabh Shukla; Nicole F Steinmetz
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.